What is ProteinQure?
ProteinQure operates at the intersection of biotechnology and computational science, specializing in the engineering of exotic peptides for targeted therapeutic applications. By leveraging its proprietary ProteinStudio platform, the company utilizes sophisticated AI models and molecular simulations to design drug-like peptides that facilitate tissue-specific delivery. This approach is designed to optimize therapeutic efficacy while simultaneously reducing systemic side effects, a critical objective in modern pharmacology. Through strategic partnerships with Tier 1 pharmaceutical entities, ProteinQure is validating its technology in real-world clinical contexts, positioning itself as a key innovator in the development of next-generation therapeutics. The company's focus on precision medicine aligns with the broader industry shift toward highly personalized and effective treatment modalities.
How much funding has ProteinQure raised?
ProteinQure has raised a total of $15M across 2 funding rounds:
Angel/Seed
$4M
Series A
$11M
Angel/Seed (2019): $4M with participation from 8VC, iNovia, Global Founders Capital, Golden Ventures, Felicis Ventures, and Tom Williams
Series A (2025): $11M, investors not publicly disclosed
Key Investors in ProteinQure
Global Founders Capital
Global Founders Capital is a global early-stage investor that empowers gifted entrepreneurs by backing them from pre-seed to IPO, focusing on category-defining ventures.
iNovia
iNovia Capital is a full-stack venture firm that partners with founders to build enduring global technology companies by prioritizing human capital.
Golden Ventures
Golden Venture Partners is a seed and early-stage venture capital fund that provides mentorship and capital to entrepreneurs leveraging the potential of new technology products.
What's next for ProteinQure?
With this latest infusion of capital, ProteinQure is well-positioned to scale its computational discovery engine and deepen its collaborative efforts with global pharmaceutical partners. The company's strategic roadmap likely involves expanding its internal pipeline of therapeutic candidates and enhancing the predictive capabilities of its AI models. As the firm moves into this more mature lifecycle stage, the focus will shift toward accelerating the transition of its lead peptide candidates into preclinical and clinical development. By maintaining its commitment to rigorous computational validation, ProteinQure aims to solidify its market position as a leader in the design of high-value, exotic peptides, ultimately transforming patient care outcomes through its unique technological architecture.
See full ProteinQure company page
